A systematic review spanning over one million patients evaluated respiratory safety signals across GLP-1 receptor agonists, finding common upper airway events that appear comparable to controls while highlighting rare serious respiratory signals. The study’s dataset scale makes it a practical reference for post-marketing safety surveillance and clinical risk counseling. Importantly, the review suggests that the most frequently observed respiratory outcomes may not represent a clear GLP-1-specific safety escalation, while still flagging the need to monitor uncommon events. This kind of signal mapping supports more nuanced pharmacovigilance rather than broad safety narratives. For biotech and pharma teams, the analysis offers a structured view of how event types cluster across drugs, enabling faster follow-up if specific rare signals become statistically or clinically significant. Clinicians and safety committees are likely to use the findings when weighing benefits for obesity and diabetes patients against the evolving body of respiratory adverse-event data.